Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Surrozen, Inc. (SRZN : NSDQ)

• Company Description    Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as Consonance-HFW Acquisition Corp., is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 44

• Price / Volume Information    Yesterday's Closing Price: $26.37 Daily Weekly Monthly 20 Day Moving Average: 93,152 shares Shares Outstanding: 11.61 (millions) Market Capitalization: $306.16 (millions) Beta: 0.59 52 Week High: $35.00 52 Week Low: $7.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.92% -18.13% 12 Week 2.41% -5.33% Year To Date 16.68% 10.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 171 Oyster Point Blvd Suite 400 - South San Francisco,CA 94080 USA ph: 650-489-9000 fax: - investorinfo@surrozen.com http://www.surrozen.com

• General Corporate Information    Officers Craig Parker - President and Chief Executive Officer and Director David J. Woodhouse - Chair of the Board of Directors Andrew Maleki - Chief Financial Officer Anna Berkenblit - Director Christopher Chai - Director Peer Information Surrozen, Inc. (GSAC) Surrozen, Inc. (CASIF) Surrozen, Inc. (ALCD.) Surrozen, Inc. (OMNN) Surrozen, Inc. (CGPI.) Surrozen, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 86889P208 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 11.61 Most Recent Split Date: 12.00 (0.07:1) Beta: 0.59 Market Capitalization: $306.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 40.85 EPS Growth vs. Year Ago Period: -47.92% vs. Previous Quarter: 39.00% Sales Growth vs. Year Ago Period: 408.65% vs. Previous Quarter: 846.97% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - -4,055.04 ROA 03/31/26 - -154.08 12/31/25 - -118.00 09/30/25 - -88.90 Current Ratio 03/31/26 - 11.91 12/31/25 - 9.22 09/30/25 - 13.15 Quick Ratio 03/31/26 - 11.91 12/31/25 - 9.22 09/30/25 - 13.15 Operating Margin 03/31/26 - -2,139.26 12/31/25 - -3,481.05 09/30/25 - -2,220.20 Net Margin 03/31/26 - -4,810.50 12/31/25 - -7,476.67 09/30/25 - -2,909.10 Pre-Tax Margin 03/31/26 - -4,571.14 12/31/25 - -6,960.77 09/30/25 - -2,411.38 Book Value 03/31/26 - -23.96 12/31/25 - -19.21 09/30/25 - -2.74 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©